Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

24/11/2015 - 2 minutes

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU.

bms_lps_finance_immunoncologyBristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a European Healthcare Fund, the first of its kind for BMS, which hails from New York (US).

Many will agree, that BMS is often considered the leader in Immuno-oncology. The range of its resources and clout in the field has granted it first pick for many up and coming blockbusters in Cancer. Indeed, their PD-1 immune checkpoint inhibitor Nivolumab was the first metastatic non-small cell lung cancer (NSCLC) treatment to have been granted EMA approval in over a decade in the EU.

Another investment BMS secured is the ‘Monster Deal’ of €408M with French Innate Pharma, for its phase II combo trial of the monoclonal antibody drug lirilumab which targets Chronic myeloid leukemia (CML).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: